Latest News

Date Title Topic
16 Dec 2013 Obinutuzumab/Chlorambucil in the First-Line Treatment of Older CLL Patients Cancer in Special Situations - Haematologic malignancies - Anticancer agents & Biologic therapy
13 Dec 2013 ESMO Press Release: Defending Medical Oncology to Assure Quality Care for Cancer Patients
12 Dec 2013 Phase III Study of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukaemia Haematologic malignancies - Anticancer agents & Biologic therapy
11 Dec 2013 CALR Mutations in Myeloproliferative Neoplasms Translational research - Haematologic malignancies
Pre-IMPAKT 2014 Training Course
09 Dec 2013 Learning From the FDA Breakthrough Therapies Pathway Bioethics, legal and economic issues - Anticancer agents & Biologic therapy
Alan Howard, ESMO’s Chief Executive Officer since 2009, has announced he is stepping down, to become effective as of January 2014.
05 Dec 2013 APO-SYS: How Modulation of Apoptosis Can be Used in the Treatment of Cancer and AIDS Translational research
ESMO German National Representative Elections
04 Dec 2013 Onartuzumab in Combination with Erlotinib in Patients with Advanced NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
02 Dec 2013 Exome Sequencing Identifies Frequent Inactivating Mutations in Intrahepatic Cholangiocarcinomas Translational research - Gastrointestinal cancers
29 Nov 2013 European Medicines Agency Recommends Changes in Use of Ponatinib in Order to Minimise Risk of Thrombosis Anticancer agents & Biologic therapy
28 Nov 2013 ESMO Press Release: Untreated Cancer Pain a ‘Scandal of Global Proportions,’ Survey Shows Palliative and supportive care
27 Nov 2013 European Medicines Agency Issues Positive Recommendation on Generic Zoledronic Acid Palliative and supportive care